Recruiting

Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression

Researchers hope to see if the data smartphones collect continuously can be used to predict if patient's depression symptoms will return. They will do this by collecting data from patient's smartphones and comparing it to their depression symptoms. If this method is successful, researchers could develop a smartphone application to help healthcare providers better monitor patient's depression and intervene earlier if symptoms return.

ClinicalTrials.gov IDNCT07174557

PhaseNA

Enrollment320

SponsorDartmouth-Hitchcock Medical Center

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Depression, Major Depressive Disorder

About this study

Interventions

Other: MoodTriggers Application — The Mood Triggers application, developed by Dr. Jacobson, will be used for collecting smartphone sensor data. This HIPAA-compliant app has been incorporated into various projects at Dartmouth, Stanford, and MGH/Harvard, with development supported by NIDA, NIMHD, NCI, and the Department of Veterans Affairs. The Mood Triggers app will capture a wide range of metrics, including psychomotor agitation, sleep disturbances, low behavioral activation, social contact, exposure to natural light, heart rate, heart rate variability, and screen time. The app also tracks the patient's screen time and app usage data. The Mood Triggers App will be installed on the smartphones at time of informed consent for all 120 patients enrolled in Phase 1 and for 100 clinical trial participants randomized to the "early warning system" (intervention arm) in Phase 2. Data will be collected from the Mood Triggers App starting on day of discharge from care and for 6 months post-discharge date.

Primary outcomes

Monthly depression relapse (discharge, 6-months post-discharge)

Eligibility information

Inclusion Criteria: * Adult patients (18 years or older) * Treated for depression within Dartmouth Health collaborative care model (CoCM) sites who are discharged from CoCM without depression (PHQ-9 \< 10) * Have access to and ability to use a smartphone (Android version ≥ 6 or iOS version ≥ 11). Exclusion Criteria: * Identified as high risk due to active suicidality, psychosis, or bipolar disorder - Discharged from CoCM with ongoing depressive symptoms (PhQ-9 \> 10

Study locations

Dartmouth College, Hanover, New Hampshire 03755 United States
Dartmouth-Hitchcock Clinics, Lebanon, New Hampshire 03766 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.